Reivindicaciones
1. Biomaterial for suturing characterised by : a) a support material b) a cellular population with proliferative and/or differentiation capacity coating the said support material. 2. Biomaterial, according to claim 1, characterised in that the support material is absorbable or non-absorbable thread. 3. Biomaterial, according to claims 1-2, characterised in that the support material is natural or synthetic thread. 4. Biomaterial, according to claims 1-3, characterised in that the support material is thread with a monofilament or multifilament structure. 5. Biomaterial, according to any of the previous claims, characterised in that the support material is a suturing thread joined to a needle. 6. Biomaterial, according to claim 1, characterised in that the support material is a staple. 7. Biomaterial, according to claims 1-6, characterised in that the cellular population of the coating is composed of stem cells. 8. Biomaterial, according to claims 1-6, characterised in that the cellular population of the coating is composed of adult multipotent stem cells. 9. Biomaterial, according to claims 1-6, characterised in that the cellular population of the coating is composed of adult multipotent mesodermal stem cells. 10. Biomaterial, according to any one of claims 1-6, characterised in that the cellular population of the coating is composed of adult multipotent stem cells derived from adipose tissue. 11. Biomaterial, according to any one of claims 1-6, characterised in that the cellular population of the coating is composed of cells which express at least one characteristic of a specialised cell. 12. Biomaterial, according to claim 11, characterised in that the cellular population of the coating of the support material is selected from among cells that express at least one characteristic of an epithelial cell, an endothelial cell, an adipocyte, miocyte chondrocyte, osteocyte, neuron, astrocyte, oligodentrocyte, hepatocyte or pancreatic cell. 13. Biomaterial, according to any one of the previous claims, characterised in that the cellular population of the coating for the support material is a heterogeneous cellular population. 14. Biomaterial, according to any one of the previous claims, characterised in that the cellular population of the coating for the support material contains genetically modified cells. 15. Biomaterial, according to the previous claim, characterised in that the cellular population of the coating for the support material contains modified cells with a gene that codes a protein involved in tissue repair. 16. Biomaterial, according to any one of the previous claims, characterised in that the cellular population of the coating for the support material contains an autologous, alogenic or xenogenic cellular population or a combination of these. 17. Method for preparing the biomaterial, according to any one of the previous claims, characterised by : • Expanding the cellular population of choice • Immersion of the suturing material in an appropriate culturing medium for that cellular population. • Inoculating a suspension of the previously cultured cellular population onto the suturing material. • Culturing this preparation under the proper conditions. • Isolating the suturing material with the right cellular coating. 18. Method for preparing the biomaterial, according to the previous claim, characterised in that the cellular population for the coating is joined to the support material by adhesion. 19. Method for preparing the biomaterial, according to claim 18, characterised in that it also includes a previous coating of the support material that facilitates the adherence of the cellular population. 20. Method for preparing the biomaterial, according to claim 19, characterised in that the coating material is selected from a group composed of: peptides, protein antigens, sugars and lipids. 21. Method for preparing the biomaterial, according to claim 19, characterised in that the coating material is composed of extracellular matrix proteins from eukaryote cells or antibodies. 22. Biomaterial for suturing, according to claims 1-16, characterised in that it is used in therapy. 23. Biomaterial for suturing, according to claims 1-16, characterised by in that it is used for bringing the edges of the tissue of accidental or surgical wounds together and in tissue repair. 24. Biomaterial for suturing, according to claims 1-16, characterised in that it is used in hemostasis, organ transplants, surgery of the gastrointestinal track, surgery of the urogenital tract, surgery of the respiratory tract, eye surgery, vascular surgery, plastic and reconstructive surgery, surgery on muscle tissue, epithelial tissue, nerve tissues and the repair of tendons, osseous tissue and cartilaginous tissue. 25. Biomaterial for suturing, according to claims 1-15, characterised in that it includes a cellular population for coating the autologous support material for use in cases where the local inflammatory reaction generated may harm the results of the surgical procedure. 26. Use of the biomaterial for suturing, according to claims 1-16, to prepare a material characterised in that it is useful for bringing the edges of tissue together in suturing accidental or surgical wounds and for tissue repair. 27. Use of the biomaterial for suturing, according to claims 1-16, to prepare a material characterised in that it is useful for bringing the edges of tissue together in suturing intestinal anastomosis. 28. Use of the biomaterial for suturing, according to claims 1-16, characterised in that it holds prostheses in place.
